Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

SRP-1003

Oligonucleotide · developed by Sarepta Therapeutics

Phase 1/2 Most advanced trial
SRPT Developer
1 Registered trials

What is SRP-1003?

SRP-1003 is an agent given by subcutaneous injection and studied in myotonic dystrophy type 1.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
ARO-DM1 IV Infusion
Drug type
Oligonucleotide
Therapy area
Musculoskeletal
Developer
Sarepta Therapeutics, Inc. (SRPT)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06138743 Phase 1/2 Myotonic Dystrophy 1 Enrolling by invitation SRPT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Myotonic Dystrophy 1

More from Sarepta Therapeutics

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the SRPT page.

Follow SRPT, the company behind SRP-1003

See SRPT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SRPT catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.